PHILADELPHIA — In a period of high-intensity advocacy spanning both coasts, the leadership of METAvivor, a non-profit organization dedicated to funding research for metastatic breast cancer (MBC), has completed a series of strategic engagements aimed at reshaping the landscape of oncology research and patient support. Led by President Kelly Shanahan, M.D., the organization’s recent activities highlight a growing synergy between pharmaceutical stakeholders, advocacy groups, and the patient community.
Dr. Shanahan, a former obstetrician-gynecologist turned patient-advocate, recently returned from a dual-city mission that included high-level "Insight Exchanges" with Genentech in San Francisco and the 20th annual Living Beyond Breast Cancer (LBBC) Metastatic Breast Cancer Conference in Philadelphia. These events serve as a critical nexus for the MBC community, which continues to fight for a larger share of research funding and clinical attention.
Main Facts: A Dual Mission of Science and Support
The recent advocacy circuit served two primary functions: the advancement of patient-centric drug development and the strengthening of the MBC community’s social infrastructure. At the core of these efforts is the reality of metastatic breast cancer—Stage IV disease where the cancer has spread beyond the breast to vital organs such as the bones, liver, lungs, or brain. While early-stage breast cancer enjoys a high survival rate and significant public visibility, MBC remains incurable, claiming approximately 42,000 lives annually in the United States alone.
Key developments from the recent advocacy tour include:
- Strategic Industry Collaboration: Dr. Shanahan represented METAvivor at Genentech’s "Insight Exchange" and "Experience Exchange." These forums brought together representatives from over 125 organizations, covering a vast spectrum of diseases, to discuss oncology-specific challenges and broader patient experience metrics.
- National Recognition for Advocacy: Both Dr. Shanahan and fellow METAvivor board member Janice Cowden were honored as "Changemakers" by Living Beyond Breast Cancer. This award recognizes individuals who have made significant contributions to the MBC community through policy advocacy, education, and peer support.
- Organizational Mobilization: METAvivor demonstrated a robust physical presence in Philadelphia, with eight board members and Executive Director Crystal Moore attending the LBBC conference. This represented a rare in-person gathering for a leadership team that typically operates via digital platforms.
- Clinical Breakthroughs: In a significant personal and scientific update, Dr. Shanahan reported that her current clinical trial is showing objective success. After two months of treatment, scans indicate a reduction in activity across all her metastatic sites, providing a tangible example of the potential for research to extend the lives of Stage IV patients.
Chronology: From the West Coast to the Birthplace of Independence
The advocacy marathon began in San Francisco, California, where Dr. Shanahan engaged with Genentech, one of the world’s leading biotech companies. The "Insight Exchange" focused specifically on the oncology pipeline, looking at how patient perspectives can be integrated into the design of clinical trials to improve recruitment, retention, and quality of life. This was followed by the "Experience Exchange," a broader summit that allowed for cross-pollination between different disease advocacy groups, identifying common hurdles in the American healthcare system.
Following the West Coast meetings, the focus shifted to the East Coast for the 20th Living Beyond Breast Cancer MBC Conference in Philadelphia.
Friday – Sunday: The LBBC Conference
The Philadelphia gathering served as both a professional symposium and a communal retreat. For the METAvivor board, the conference was an opportunity to move beyond the "tiny squares on Zoom" and engage in face-to-face strategic planning.
During the conference, Dr. Shanahan pivoted from her usual role as a data-driven clinical expert to participate in a panel titled "The Emotional Impact of Living Long-Term with MBC." This session addressed the psychological toll of a terminal diagnosis and the "survivor’s guilt" or anxiety that often accompanies long-term survival in a community where many friends and colleagues are lost to the disease.
Throughout the weekend, METAvivor maintained a high-visibility presence through an information booth manned by board member Tim Bigelow. The booth served as a recruitment hub for new volunteers, specifically those interested in grant review—a cornerstone of METAvivor’s mission—and peer-to-peer leadership training.
Supporting Data: The Funding Gap and the METAvivor Model
The urgency of Dr. Shanahan’s advocacy is backed by stark disparities in breast cancer research funding. Historically, while breast cancer receives billions in global funding, only an estimated 2% to 5% of those funds are directed toward research into metastatic disease—the only stage of breast cancer that kills.
METAvivor was founded to bridge this "metastatic gap." The organization’s operational model is unique in the non-profit sector:
- 100% Mission Funding: 100% of all individual donations and proceeds from METAvivor fundraisers go directly to MBC research grants.
- Peer-Led Advocacy: The organization is led by patients living with the disease, ensuring that the research funded is focused on extending life and improving treatment tolerability.
- The Impact of Research: Dr. Shanahan’s own clinical trial success serves as a data point for the efficacy of modern precision medicine. The reduction in activity of "many metastases" within a 60-day window underscores the rapid pace of innovation in targeted therapies and the necessity of patient participation in trials.
The LBBC conference also highlighted the importance of peer-to-peer support. METAvivor is currently expanding its network of trained leaders to start local support groups, addressing a critical need for specialized mental health resources for Stage IV patients who often find traditional "pink ribbon" support groups (focused on "beating" cancer) to be alienating or inappropriate for their circumstances.
Official Responses and Perspectives
The recognition of Dr. Shanahan and Janice Cowden as "Changemakers" by LBBC reflects a broader acknowledgment within the medical community of the power of the "expert patient."
"I was honored to talk about how getting involved with MBC advocacy in general, and METAvivor in particular, has really helped me cope with this diagnosis and the loss of my career as an OB/GYN," Dr. Shanahan stated. Her perspective highlights a common theme among MBC advocates: the transition of grief and loss into productive, life-saving activism.
Living Beyond Breast Cancer, in their citation for the Changemaker award, emphasized that the work of advocates like Cowden and Shanahan is essential for ensuring that "every moment counts." By pushing for legislative changes and increased research appropriations, these leaders are moving the needle from MBC being a terminal diagnosis to a manageable chronic condition.
Executive Director Crystal Moore emphasized the organizational strength gained from the Philadelphia meeting. The presence of board members from across the country—stretching from Massachusetts to Florida and New Jersey to California—underscores the national reach of the METAvivor movement. The organization continues to call for volunteers to join their "Take Action" initiatives, which include legislative lobbying and scientific grant review.
Implications: The Future of Metastatic Advocacy
The activities of this past month signal a maturing of the MBC advocacy movement. No longer content with merely "raising awareness," organizations like METAvivor are now deeply embedded in the corporate and scientific decision-making processes.
The Shift to Patient-Centricity
The involvement of METAvivor in Genentech’s exchanges suggests that the pharmaceutical industry is increasingly recognizing that patients are not just subjects of research, but partners in it. By integrating patient insights into the "Experience Exchange," companies can better understand the real-world barriers to treatment adherence, such as "financial toxicity" and the emotional burden of long-term treatment.
The Evolution of the "Survivor" Narrative
The panel on the emotional impact of long-term survival points to a shift in the oncology narrative. As research (funded by groups like METAvivor) successfully extends the lives of MBC patients, a new demographic is emerging: the "long-term thriver." This group requires specialized medical and psychological care that differs significantly from both early-stage survivors and end-of-life hospice care.
The Urgency of Continued Funding
Despite Dr. Shanahan’s positive clinical trial results, the underlying reality remains: the "trial drugs" are a lifeline, not a cure. The continued mobilization of volunteers for grant reviews and support group leadership is essential for maintaining the momentum of the MBC movement.
As METAvivor looks toward the remainder of the year, the focus remains on the "Take Action" page—a portal for patients and allies to contribute to a future where metastatic breast cancer is no longer a death sentence. The "exhausted but energized" state of its leadership reflects a community that is racing against time, fueled by small victories in the lab and large victories in the halls of advocacy.
For more information on how to support metastatic breast cancer research or to become a peer leader, visit METAvivor.org.
About the Author
